Showing results (11-20 of 183) with videos related to
Sort By:
Pageof 19
Blood Advances|March 26, 2020
Gilteritinib: potent targeting of FLT3 mutations in AMLMark Levis, Alexander E PerlClinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2022
Shall We Dance: Evolving Partnerships of Targeted Therapies for AMLAlexander E Perl, Paresh VyasExpert Review of Clinical Pharmacology|August 28, 2019
Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemiaChristine M McMahon, Alexander E PerlLeukemia & Lymphoma|September 21, 2018
Management of primary refractory acute myeloid leukemia in the era of targeted therapiesChristine M McMahon, Alexander E PerlCancer Journal (Sudbury, Mass.)|January 24, 2022
Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia: The Case for Total TherapyAlexander E Perl, Keith W PratzClinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2018
Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 InhibitorsGregory W Schwartz, Bryan Manning, Yeqiao Zhou, et al.The Journal of Clinical Investigation|March 20, 2020
Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALLChristian Hurtz, Gerald B Wertheim, Joseph P Loftus, et al.The Journal of Clinical Investigation|December 16, 2010
BCR-ABL kinase is dead; long live the CML stem cellAlexander Perl, Martin CarrollGenome Biology|September 28, 2014
Dynamic evolution of clonal epialleles revealed by methcloneSheng Li, Francine Garrett-Bakelman, Alexander E Perl, et al.Pageof 19